166 related articles for article (PubMed ID: 15833076)
1. Efalizumab: continuous therapy for chronic psoriasis.
Cather JC; Menter A
Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
[TBL] [Abstract][Full Text] [Related]
2. [Efalizumab. Long-term treatment of psoriasis].
Prinz JC
Hautarzt; 2005 Sep; 56(9):812-8. PubMed ID: 16096737
[TBL] [Abstract][Full Text] [Related]
3. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
4. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
6. Efalizumab in the treatment of psoriasis.
Gupta AK; Cherman AM
J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
[TBL] [Abstract][Full Text] [Related]
7. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
9. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
Cather JC; Cather JC; Menter A
Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
[TBL] [Abstract][Full Text] [Related]
11. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program.
Foley P; Freeman M; Gebauer K; Murrell D; Shumack S; Tyson C; Varigos G
Int J Dermatol; 2009 Dec; 48(12):1376-84. PubMed ID: 19930495
[TBL] [Abstract][Full Text] [Related]
12. Efalizumab.
Wellington K; Perry CM
Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
[TBL] [Abstract][Full Text] [Related]
13. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.
Frampton JE; Plosker GL
Am J Clin Dermatol; 2009; 10(1):51-72. PubMed ID: 19170413
[TBL] [Abstract][Full Text] [Related]
14. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
Gottlieb AB; Miller B; Lowe N; Shapiro W; Hudson C; Bright R; Ling M; Magee A; McCall CO; Rist T; Dummer W; Walicke P; Bauer RJ; White M; Garovoy M
J Cutan Med Surg; 2003; 7(3):198-207. PubMed ID: 12717587
[TBL] [Abstract][Full Text] [Related]
16. [Which patient is a candidate for treatment with efalizumab and why?].
Puig L
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():51-61. PubMed ID: 18341853
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
18. Efalizumab in the treatment of psoriasis.
Leonardi CL
Dermatol Ther; 2004; 17(5):393-400. PubMed ID: 15379774
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
20. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
